ISMIGEN TABLETS
No reviews
- International Name (active ingredient): Ismigen
-
Manufacturer: GMP
- Country: Georgia
-
Issuing mode: Group III (without a prescription)
- Release form: 10 or 30 tablets in blisters; secondary packaging - in a cardboard box.
Acute, subacute, recurrent or chronic infections of the upper respiratory tract and bronchopulmonary tract.
Composition
One tablet of the drug contains 50 mg of lyophilized bacterial lysate, of which 7 mg of lysate corresponds to: Staphylococcus aureus - 6 billion, Streptococcus pyogenes - 6 billion, Streptococcus viridans - 6 billion, Klebsiella pneumoniae - 6 billion, Klebsiella ozaenae - 6 billion, Haemophilus influenzae B - 6 billion, Neisseria catarrhalis - 6 billion, Diplococcus pneumoniae - 6 billion (the latter bacteria contain different types, 1 billion each - TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24), and 43 mg of glycolic acid - for the lyophilization process.
Excipients: microcrystalline cellulose, dibasic calcium phosphate, magnesium stearate, ammonium glycyrrhizinate, silicon dioxide, menthol essence.
Excipients: microcrystalline cellulose, dibasic calcium phosphate, magnesium stearate, ammonium glycyrrhizinate, silicon dioxide, menthol essence.
Pharmacological properties
Combined immunostimulating drug of bacterial origin, obtained by mechanical lysis of microbial cells. Ismigen increases the body's defenses against microorganisms that cause upper respiratory tract infections of the bronchopulmonary tract. Stimulates both local cellular and humoral immune responses in the mucous membrane of the respiratory system, as well as systemic immune responses.
The protective effect of Ismigen against experimental infections has been established by immunoelectrodiffusion, which is manifested by the induction of specific antibodies - immunoglobulins (IgA and IgG), stimulation of T and B lymphocytes, ciliary cells, production of interleukins, stimulation of phagocytosis and macrophage function. No depressant or stimulating effect of the drug on the cardiovascular or respiratory systems has been detected.
The immunostimulating properties of Ismigen are due to:
- restoration of impaired functions of T-lymphocyte membranes in selective IgA deficiency
- significant increase in the response, which is not characteristic of mitoclonal mitogens in a healthy or diseased body
- slight increase in the circulation of immune complexes.
The specific immune response of patients treated with Ismigen was demonstrated by in vitro stimulation of lymphocytes, which affects the supporting effect of the macrophage-monocyte system.
Combined immunostimulating drug of bacterial origin, obtained by mechanical lysis of microbial cells. Ismigen increases the body's defenses against microorganisms that cause upper respiratory tract infections of the bronchopulmonary tract. Stimulates both local cellular and humoral immune responses in the mucous membrane of the respiratory system, as well as systemic immune responses.
The protective effect of Ismigen against experimental infections has been established by immunoelectrodiffusion, which is manifested by the induction of specific antibodies - immunoglobulins (IgA and IgG), stimulation of T and B lymphocytes, ciliary cells, production of interleukins, stimulation of phagocytosis and macrophage function. No depressant or stimulating effect of the drug on the cardiovascular or respiratory systems has been detected.
The immunostimulating properties of Ismigen are due to:
- restoration of impaired functions of T-lymphocyte membranes in selective IgA deficiency
- significant increase in the response, which is not characteristic of mitoclonal mitogens in a healthy or diseased body
- slight increase in the circulation of immune complexes.
The specific immune response of patients treated with Ismigen was demonstrated by in vitro stimulation of lymphocytes, which affects the supporting effect of the macrophage-monocyte system.
Directions and dosage
Oral tablets for children and adults.
Adults and children over 12 years of age are prescribed Ismigen 7 mg (1 tablet) for sublingual administration; children from 6 months to 12 years of age - 3.5 mg (1/2 tablet) for sublingual administration. For young children, it is permissible to dissolve the powdered tablet in a small amount of liquid (tea, juices).
Treatment of acute processes: 1 tablet once a day for sublingual administration (after taking the drug, it is necessary to limit food intake for at least half an hour). It is prescribed every day for at least 10 days, until the symptoms disappear. The therapeutic course involves taking 10 tablets. Long-term therapeutic and prophylactic use: 1 tablet sublingually once a day for 10 days. After a 20-day break, the next month it is necessary to repeat the 10-day course. The full course of treatment, when the maximum immunotherapeutic effect is achieved, is 3 months. To complete a full course, you need to take 30 Ismigen tablets.
Oral tablets for children and adults.
Adults and children over 12 years of age are prescribed Ismigen 7 mg (1 tablet) for sublingual administration; children from 6 months to 12 years of age - 3.5 mg (1/2 tablet) for sublingual administration. For young children, it is permissible to dissolve the powdered tablet in a small amount of liquid (tea, juices).
Treatment of acute processes: 1 tablet once a day for sublingual administration (after taking the drug, it is necessary to limit food intake for at least half an hour). It is prescribed every day for at least 10 days, until the symptoms disappear. The therapeutic course involves taking 10 tablets. Long-term therapeutic and prophylactic use: 1 tablet sublingually once a day for 10 days. After a 20-day break, the next month it is necessary to repeat the 10-day course. The full course of treatment, when the maximum immunotherapeutic effect is achieved, is 3 months. To complete a full course, you need to take 30 Ismigen tablets.
Side effects
Rarely may occur:
On the part of the digestive system: pain in the epigastrium, nausea, vomiting, diarrhea.
Miscellaneous: increased body temperature, allergic skin reactions.
Contraindications
Hypersensitivity to the components of the drug.
Pregnancy and lactation
Although the toxic effects of Ismigen on animals have not been identified, it is recommended to refrain from taking the drug during the first 3 months of pregnancy or the expected pregnancy.
Overdose: Cases of overdose have not been described.
Interaction with other drugs: No interaction with other drugs, including antibiotics, has been identified.
Storage conditions and terms: The shelf life of the drug is 3 years.
Store at a temperature of 15-25°C, out of the reach of children!
The dispensing rule in a pharmacy: issued without a prescription